304 related articles for article (PubMed ID: 35428327)
1. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
Ristau J; Hörner-Rieber J; Buchele C; Klüter S; Jäkel C; Baumann L; Andratschke N; Garcia Schüler H; Guckenberger M; Li M; Niyazi M; Belka C; Herfarth K; Debus J; Koerber SA
Radiat Oncol; 2022 Apr; 17(1):75. PubMed ID: 35428327
[TBL] [Abstract][Full Text] [Related]
2. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.
Ugurluer G; Atalar B; Zoto Mustafayev T; Gungor G; Aydin G; Sengoz M; Abacioglu U; Tuna MB; Kural AR; Ozyar E
Br J Radiol; 2021 Jan; 94(1117):20200696. PubMed ID: 33095670
[TBL] [Abstract][Full Text] [Related]
8. Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
Schaule J; Chamberlain M; Wilke L; Baumgartl M; Krayenbühl J; Zamburlini M; Mayinger M; Andratschke N; Tanadini-Lang S; Guckenberger M
Radiat Oncol; 2021 Sep; 16(1):189. PubMed ID: 34565439
[TBL] [Abstract][Full Text] [Related]
9. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter
Fink CA; Ristau J; Buchele C; Klüter S; Liermann J; Hoegen-Saßmannshausen P; Sandrini E; Lentz-Hommertgen A; Baumann L; Andratschke N; Baumgartl M; Li M; Reiner M; Corradini S; Hörner-Rieber J; Bonekamp D; Schlemmer HP; Belka C; Guckenberger M; Debus J; Koerber SA
Clin Transl Radiat Oncol; 2024 May; 46():100771. PubMed ID: 38586081
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
13. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation.
Potkrajcic V; Gani C; Fischer SG; Boeke S; Niyazi M; Thorwarth D; Voigt O; Schneider M; Mönnich D; Kübler S; Boldt J; Hoffmann E; Paulsen F; Mueller AC; Wegener D
Curr Oncol; 2024 May; 31(5):2679-2688. PubMed ID: 38785484
[TBL] [Abstract][Full Text] [Related]
14. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study.
Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P
Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001
[TBL] [Abstract][Full Text] [Related]
15. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941
[TBL] [Abstract][Full Text] [Related]
17. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer.
Fink CA; Buchele C; Baumann L; Liermann J; Hoegen P; Ristau J; Regnery S; Sandrini E; König L; Rippke C; Bonekamp D; Schlemmer HP; Debus J; Koerber SA; Klüter S; Hörner-Rieber J
Front Oncol; 2024; 14():1308406. PubMed ID: 38425342
[TBL] [Abstract][Full Text] [Related]
19. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.
Draulans C; van der Heide UA; Haustermans K; Pos FJ; van der Voort van Zyp J; De Boer H; Groen VH; Monninkhof EM; Smeenk RJ; Kunze-Busch M; De Roover R; Depuydt T; Isebaert S; Kerkmeijer LGW
Radiother Oncol; 2020 Jun; 147():92-98. PubMed ID: 32247206
[TBL] [Abstract][Full Text] [Related]
20. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
